SCHEMBL13087490

SCHEMBL13087490

N#Cc1ccc(-c2cc(NC3CCN(S(=O)(=O)C4CC4)CC3)c3cnccc3c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR6 P51684 6/20 0.46
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
IRAK4 Q9NWZ3 1/20 0.41
PRKCZ Q05513 7/20 0.41
PRKD2 Q9BZL6 6/20 0.41
CDK2 P24941 3/20 0.41
CCNA2 P20248 2/20 0.41
CCNK O75909 1/20 0.40
CDK12 Q9NYV4 1/20 0.40
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
CCNT1 O60563 1/20 0.38
CDK1 P06493 1/20 0.38
CDK4 P11802 1/20 0.38
CCNB1 P14635 1/20 0.38
CCND1 P24385 1/20 0.38
CCNE1 P24864 1/20 0.38
CCND3 P30281 1/20 0.38
CDK7 P50613 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13087664 0.91 CYP11B1 (0.42) CCR6CYP11B1CYP11B2IRAK4PRKCZ
SCHEMBL13087640 0.91 CCR6 (0.46) CCR6CYP11B1CYP11B2IRAK4PRKCZ
SCHEMBL13089969 0.90 ROCK2 (0.43) CCR6CYP11B1CYP11B2IRAK4PRKCZ
SCHEMBL13087344 0.90 CCR6 (0.46) CCR6CYP11B1CYP11B2PRKCZPRKD2
SCHEMBL13087357 0.89 CNR1 (0.40) CCR6CYP11B1CYP11B2IRAK4PRKCZ
SCHEMBL13090015 0.89 CYP17A1 (0.41) CCR6CYP11B1CYP11B2IRAK4PRKCZ
SCHEMBL13087291 0.89 CYP17A1 (0.43) CYP11B1PRKCZPRKD2CDK2CCND1
SCHEMBL13087372 0.88 CCR6 (0.40) CCR6CYP11B1CYP11B2IRAK4PRKCZ
SCHEMBL13087300 0.88 TNF (0.41) CCR6CYP11B1CYP11B2PRKCZPRKD2
SCHEMBL13087444 0.88 CYP11B1 (0.43) CCR6CYP11B1CYP11B2IRAK4PRKCZ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof RELA, NFKBIA, NFKB2 CCR6 3313/4885CYP11B1 353/4885CYP11B2 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.